– TaiMed Biologics anuncia en la CROI 2025 los resultados de los últimos datos de fase 2a sobre la terapia de mantenimiento de acción prolongada contra el VIH La combinación TMB-365/TMB-380 demuestra la suspensión viral sin necesidad de pruebas de susceptibilidad TaiMed Biologics…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.